Plasma proteins interaction with curcumin nanoparticles: Implications in cancer therapeutics

Current Drug Metabolism

Volumn 14, Issue 4, 2013, Pages 504-515

  Yallapu, Murali M ^a   Ebeling, Mara C ^a   Jaggi, Meena ^a,b   Chauhan, Subhash C ^a,b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Bioavailability; Cancer therapeutics; Drug delivery; Nanomedicine; Polyphenol; Protein corona

Indexed keywords

CURCUMIN; NANOPARTICLE; PIPERINE; PLASMA PROTEIN; SERUM ALBUMIN;

ARTICLE; ATOMIC FORCE MICROSCOPY; CANCER THERAPY; CAPILLARY ELECTROPHORESIS; COMPLEX FORMATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FLUORESCENCE CORRELATION SPECTROSCOPY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; ULTRAVIOLET SPECTROSCOPY;

ANIMALS; BLOOD PROTEINS; CURCUMIN; HUMANS; NANOPARTICLES; NEOPLASMS; PROTEIN BINDING;

EID: 84881655252     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211314040012     Document Type: Article

References (91)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin., 2012, 62, 10-29.
2. Newman, D. J.; Cragg, G. M.; Snader, K. M. Natural products as sources of new drugs over the period. J. Nat. Prod., 2003, 66, 1022-1037. (Pubitemid 36909859)
3. Bar-Sela, G.; Epelbaum, R.; Schaffer, M. Curcumin as an anticancer agent: review of the gap between basic and clinical applications. Curr. Med. Chem., 2010, 17, 190-197.
4. Marathe, S. A.; Dasgupta, I.; Gnanadhas, D. P.; Chakravortty, D. Multifaceted roles of curcumin: two sides of a coin! Expert Opin. Biol. Ther., 2011, 11, 1485-1499.
5. Basnet, P.; Skalko-Basnet, N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules, 2011, 16, 4567-4598.
6. Gupta, S. C.; Prasad, S.; Kim, J. H.; Patchva, S.; Webb, L. J.; Priyadarsini, I. K.; Aggarwal, B. B. Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep., 2011, 28, 1937-1955.
7. Garg, A. K.; Buchholz, T. A.; Aggarwal, B. B. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid. Redox. Signal., 2005, 7, 1630-1647. (Pubitemid 41767998)
8. Shehzad, A.; Wahid, F.; Lee, Y. S. Curcumin in cancer chemopre-vention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch. Pharm., 2010, 343, 489-499.
9. Fan, X.; Zhang, C.; Liu, D. B.; Yan, J.; Liang, H. P. The Clinical Applications of Curcumin: Current State and the Future. Curr. Pharm. Des., 2013.
10. Yallapu, M. M.; Jaggi, M.; Chauhan, S. C. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov. Today, 2012, 17, 71-80.
11. Ravindranath, V.; Chandrasekhara, N. Metabolism of curcumin-studies with [3H]curcumin. Toxicology, 1981, 22, 337-344.
12. Pulla Reddy, A. C.; Sudharshan, E.; Appu Rao, A. G.; Lokesh, B. R. Interaction of curcumin with human serum albumin - a spectro-scopic study. Lipids, 1999, 34, 1025-1029. (Pubitemid 29526811)
13. Leung, M. H.; Kee, T. W. Effective stabilization of curcumin by association to plasma proteins: human serum albumin and fibrino-gen. Langmuir, 2009, 25, 5773-5777.
14. Wang, Y. J.; Pan, M. H.; Cheng, A. L.; Lin, L. I.; Ho, Y. S.; Hsieh, C. Y.; Lin, J. K. Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal., 1997, 15, 1867-1876.
15. Barik, A.; Mishra, B.; Kunwar, A.; Priyadarsini, K. I. Interaction of curcumin with human serum albumin: Thermodynamic properties, Fluorescence energy transfer and Denaturation effects. Chem. Phys. Lett., 2007, 436, 239-243. (Pubitemid 46216984)
16. Patra, D.; Barakat, C.; Tafech, R. M. Study on effect of lipophilic curcumin on sub-domain IIA site of human serum albumin during unfolded and refolded states: a synchronous fluorescence spectro-scopic study. Colloids Surf. B: Biointerfaces, 2012, 94, 354-361.
17. Mohammadi, F.; Bordbar, A. K.; Divsalar, A.; Mohammadi, K.; Saboury, A. A. Analysis of binding interaction of curcumin and di-acetylcurcumin with human and bovine serum albumin using fluorescence and circular dichroism spectroscopy. Protein. J., 2009, 28, 189-196.
18. Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release, 2008, 132, 171-183.
19. Elsadek, B.; Kratz, F. Impact of albumin on drug delivery-new applications on the horizon. J. Control. Release, 2012, 157, 4-28.
20. Xiao, J.B.; Kai, G.Y. A review of dietary polyphenol-plasma protein interactions: Characterization, influence on the bioactivity, and structure-affinity relationship. Crit. Rev. Food Sci. Nutr., 2012, 52, 85-101.
21. De Jong, W. H.; Borm, P. J. Drug delivery and nanoparti-cles: applications and hazards. Int. J. Nanomedicine, 2008, 3, 133-149. (Pubitemid 352042401)
22. Lynch, I.; Cedervall, T.; Lundqvist, M.; Cabaleiro-Lago, C.; Linse, S.; Dawson, K. A. The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv. Colloid. Interface. Sci., 2007, 134-135, 167-174. (Pubitemid 47614904)
23. Liu, J.; Chen, S.; Lv, L.; Song, L.; Guo, S. Recent Progresses in Studying Curcumin and Its Nano-preparations for Cancer Therapy. Curr. Pharm. Des., 2013.
24. Ji, J. L.; Huang, X. F.; Zhu, H. L. Curcumin and its formulations: potential anti-cancer agents. Anticancer Agents Med. Chem., 2012, 12, 210-218.
25. Albanese, A.; Tang, P. S.; Chan, W. C. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng., 2012, 14, 1-16.
26. Cedervall, T.; Lynch, I.; Lindman, S.; Berggard, T.; Thulin, E.; Nilsson, H.; Dawson, K. A.; Linse, S. Understanding the nanoparti-cle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl. Acad. Sci. USA., 2007, 104, 2050-2055. (Pubitemid 46391350)
27. Treuel, L.; Nienhaus, G. U. Toward a molecular understanding of nanoparticle-protein interactions. Biophys. Rev., 2012, 4, 137-147.
28. Lundqvist, M.; Stigler, J.; Cedervall, T.; Berggard, T.; Flanagan, M. B.; Lynch, I.; Elia, G.; Dawson, K. The evolution of the protein corona around nanoparticles: a test study. ACS Nano., 2011, 5, 7503-7509.
29. Lundqvist, M.; Stigler, J.; Elia, G.; Lynch, I.; Cedervall, T.; Dawson, K. A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. U S A., 2008, 105, 14265-14270.
30. Dell'Orco, D.; Lundqvist, M.; Oslakovic, C.; Cedervall, T.; Linse, S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One, 2010, 5, e10949.
31. Capriotti, A. L.; Caracciolo, G.; Cavaliere, C.; Foglia, P.; Pozzi, D.; Samperi, R.; Lagana, A. Do plasma proteins distinguish between liposomes of varying charge density? J. Proteomics, 2012, 75, 1924-1932.
32. Zhang, H.; Burnum, K. E.; Luna, M. L.; Petritis, B. O.; Kim, J. S.; Qian, W. J.; Moore, R. J.; Heredia-Langner, A.; Webb-Robertson, B. J.; Thrall, B. D.; Camp, D. G., 2nd; Smith, R. D.; Pounds, J. G.; Liu, T. Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size. Proteomics, 2011, 11, 4569-4577.
33. Simberg, D.; Park, J. H.; Karmali, P. P.; Zhang, W. M.; Merkulov, S.; McCrae, K.; Bhatia, S. N.; Sailor, M.; Ruoslahti, E. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials, 2009, 30, 3926-3933.
34. Tenzer, S.; Docter, D.; Rosfa, S.; Wlodarski, A.; Kuharev, J.; Rekik, A.; Knauer, S. K.; Bantz, C.; Nawroth, T.; Bier, C.; Sirirat-tanapan, J.; Mann, W.; Treuel, L.; Zellner, R.; Maskos, M.; Schild, H.; Stauber, R. H. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano., 2011, 5, 7155-7167.
35. Arvizo, R. R.; Giri, K.; Moyano, D.; Miranda, O. R.; Madden, B.; McCormick, D. J.; Bhattacharya, R.; Rotello, V. M.; Kocher, J. P.; Mukherjee, P. Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One, 2012, 7, e33650.
36. Desai, N.; Trieu, V.; Damascelli, B.; Soon-Shiong, P. SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. Transl. Oncol., 2009, 2, 59-64.
37. Desai, N. P.; Trieu, V.; Hwang, L. Y.; Wu, R.; Soon-Shiong, P.; Gradishar, W. J. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs, 2008, 19, 899-909.
38. Desai, N. nab-Paclitaxel (Abraxane®): an albumin-bound cytotoxic exploiting natural delivery mechanisms into tumors. Drug Delivery Report, PharmaVentures Ltd: Oxford OX4 4GA, UK, 2007; pp. 37-41.
39. Dell'orco, D.; Lundqvist, M.; Cedervall, T.; Linse, S. Delivery success rate of engineered nanoparticles in the presence of the protein corona: a systems-level screening. Nanomedicine, 2012, 8, 1271-1281.
40. Xie, X.; Tao, Q.; Zou, Y.; Zhang, F.; Guo, M.; Wang, Y.; Wang, H.; Zhou, Q.; Yu, S. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J. Agric. Food Chem., 2011, 59, 9280-9289.
41. Aleksenko, S. S.; Shmykov, A. Y.; Oszwaldowski, S.; Timerbaev, A. R. Interactions of tumour-targeting nanoparticles with proteins: potential of using capillary electrophoresis as a direct probe. Metal-lomics, 2012, 4, 1141-1148.
42. Casals, E.; Pfaller, T.; Duschl, A.; Oostingh, G. J.; Puntes, V. Time evolution of the nanoparticle protein corona. ACS Nano., 2010, 4, 3623-3632.
43. Paul, B. K.; Bhattacharjee, K.; Bose, S.; Guchhait, N. A spectro-scopic investigation on the interaction of a magnetic ferrofluid with a model plasma protein: effect on the conformation and activity of the protein. Phys. Chem. Chem. Phys., 2012, 14, 15482-15493.
44. Gebauer, J. S.; Malissek, M.; Simon, S.; Knauer, S. K.; Maskos, M.; Stauber, R. H.; Peukert, W.; Treuel, L. Impact of the nanopar-ticle-protein corona on colloidal stability and protein structure. Langmuir, 2012, 28, 9673-9679.
45. Schaefer, J.; Schulze, C.; Marxer, E. E.; Schaefer, U. F.; Wohlleben, W.; Bakowsky, U.; Lehr, C. M. Atomic force microscopy and analytical ultracentrifugation for probing nanomaterial protein interactions. ACS Nano., 2012, 6, 4603-4614.
46. Lindman, S.; Lynch, I.; Thulin, E.; Nilsson, H.; Dawson, K. A.; Linse, S. Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide co-polymer nanoparticles. Effects of particle size and hydrophobicity. Nano Lett., 2007, 7, 914-920. (Pubitemid 46717733)
47. Aggarwal, P.; Hall, J. B.; McLeland, C. B.; Dobrovolskaia, M. A.; McNeil, S. E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug. Deliv. Rev., 2009, 61, 428-437.
48. Mahon, E.; Salvati, A.; Baldelli Bombelli, F.; Lynch, I.; Dawson, K. A. Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". J. Control. Release, 2012, 161, 164-174.
49. Shaikh, J.; Ankola, D. D.; Beniwal, V.; Singh, D.; Kumar, M. N. Nanoparticle encapsulation improves oral bioavailability of curcu-min by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci., 2009, 37, 223-230.
50. Anand, P.; Nair, H. B.; Sung, B.; Kunnumakkara, A. B.; Yadav, V. R.; Tekmal, R. R.; Aggarwal, B. B. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem. Pharmacol., 2010, 79, 330-338.
51. Onoue, S.; Takahashi, H.; Kawabata, Y.; Seto, Y.; Hatanaka, J.; Timmermann, B.; Yamada, S. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J. Pharm. Sci., 2010, 99, 1871-1881.
52. Gao, Y.; Li, Z.; Sun, M.; Li, H.; Guo, C.; Cui, J.; Li, A.; Cao, F.; Xi, Y.; Lou, H.; Zhai, G. Preparation, characterization, pharma-cokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug. Dev. Ind. Pharm., 2010, 36, 1225-1234.
53. Mohanty, C.; Sahoo, S. K. The in vitro stability and in vivo phar-macokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials, 2010, 31, 6597-6611.
54. Bisht, S.; Mizuma, M.; Feldmann, G.; Ottenhof, N. A.; Hong, S. M.; Pramanik, D.; Chenna, V.; Karikari, C.; Sharma, R.; Goggins, M. G.; Rudek, M. A.; Ravi, R.; Maitra, A. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol. Cancer. Ther., 2010, 9, 2255-2264.
55. Kakkar, V.; Singh, S.; Singla, D.; Kaur, I. P. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol. Nutr. Food. Res., 2011, 55, 495-503.
56. Yu, H.; Huang, Q. Improving the oral bioavailability of curcumin using novel organogel-based nanoemulsions. J. Agric. Food. Chem., 2012, 60, 5373-5379.
57. Tsai, Y. M.; Chang-Liao, W. L.; Chien, C. F.; Lin, L. C.; Tsai, T. H. Effects of polymer molecular weight on relative oral bioavail-ability of curcumin. Int. J. Nanomed., 2012, 7, 2957-2966.
58. Wang, W.; Zhu, R.; Xie, Q.; Li, A.; Xiao, Y.; Li, K.; Liu, H.; Cui, D.; Chen, Y.; Wang, S. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int. J. Nanomed., 2012, 7, 3667-3677.
59. Feng, R.; Song, Z.; Zhai, G. Preparation and in vivo pharmacoki-netics of curcumin-loaded PCL-PEG-PCL triblock copolymeric nanoparticles. Int. J. Nanomed., 2012, 7, 4089-4098.
60. Ranjan, A. P.; Mukerjee, A.; Helson, L.; Vishwanatha, J. K. Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy. J. Nanobiotechnol., 2012, 10, 38.
61. Khalil, N. M.; Nascimento, T. C.; Casa, D. M.; Dalmolin, L. F.; Mattos, A. C.; Hoss, I.; Romano, M. A.; Mainardes, R. M. Pharma-cokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf. B: Biointerfaces, 2013, 101, 353-360.
62. Li, C.; Zhang, Y.; Su, T.; Feng, L.; Long, Y.; Chen, Z. Silica-coated flexible liposomes as a nanohybrid delivery system for enhanced oral bioavailability of curcumin. Int. J. Nanomed., 2012, 7, 5995-6002.
63. Pawar, Y. B.; Purohit, H.; Valicherla, G. R.; Munjal, B.; Lale, S. V.; Patel, S. B.; Bansal, A. K. Novel lipid based oral formulation of curcumin: development and optimization by design of experiments approach. Int. J. Pharm., 2012, 436, 617-623.
64. Jiang, X.; Weise, S.; Hafner, M.; Rocker, C.; Zhang, F.; Parak, W. J.; Nienhaus, G. U. Quantitative analysis of the protein corona on FePt nanoparticles formed by transferrin binding. J. R. Soc. Interface, 2010, 7 (1), S5-S13.
65. Maiorano, G.; Sabella, S.; Sorce, B.; Brunetti, V.; Malvindi, M. A.; Cingolani, R.; Pompa, P. P. Effects of cell culture media on the dynamic formation of protein-nanoparticle complexes and influence on the cellular response. ACS Nano., 2010, 4, 7481-7491.
66. Lartigue, L.; Wilhelm, C.; Servais, J.; Factor, C.; Dencausse, A.; Bacri, J. C.; Luciani, N.; Gazeau, F. Nanomagnetic sensing of blood plasma protein interactions with iron oxide nanoparticles: impact on macrophage uptake. ACS Nano., 2012, 6, 2665-2678.
67. Dittrich, C.; Burckhardt, C. J.; Danuser, G. Delivery of membrane impermeable cargo into CHO cells by peptide nanoparticles targeted by a protein corona. Biomaterials, 2012, 33, 2746-2753.
68. Mulik, R. S.; Monkkonen, J.; Juvonen, R. O.; Mahadik, K. R.; Paradkar, A. R. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int. J. Pharm., 2010, 398, 190-203.
69. Dilnawaz, F.; Singh, A.; Sahoo, S. K. Transferrin-conjugated cur-cumin-loaded superparamagnetic iron oxide nanoparticles induce augmented cellular uptake and apoptosis in K562 cells. Acta Biomater., 2012, 8, 704-719.
70. Rejinold, N. S.; Muthunarayanan, M.; Chennazhi, K. P.; Nair, S. V.; Jayakumar, R. Curcumin loaded fibrinogen nanoparticles for cancer drug delivery. J. Biomed. Nanotechnol., 2011, 7, 521-534.
71. Yallapu, M. M.; Gupta, B. K.; Jaggi, M.; Chauhan, S. C. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J. Colloid Interface Sci., 2010, 351, 19-29.
72. Panyam, J.; Zhou, W. Z.; Prabha, S.; Sahoo, S. K.; Labhasetwar, V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J., 2002, 16, 1217-1226. (Pubitemid 34815409)
73. Yallapu, M. M.; Ebeling, M. C.; Chauhan, N.; Jaggi, M.; Chauhan, S. C. Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes. Int. J. Nanomed., 2011, 6, 2779-2790.
74. Jedlovszky-Hajdu, A.; Bombelli, F. B.; Monopoli, M. P.; Tom-bacz, E.; Dawson, K. A. Surface coatings shape the protein corona of SPIONs with relevance to their application in vivo. Langmuir, 2012, 28, 14983-14991.
75. Yallapu, M. M.; Othman, S. F.; Curtis, E. T.; Bauer, N. A.; Chauhan, N.; Kumar, D.; Jaggi, M.; Chauhan, S. C. Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int. J. Nanomed., 2012, 7, 1761-1779.
76. Yallapu, M. M.; Othman, S. F.; Curtis, E. T.; Gupta, B. K.; Jaggi, M.; Chauhan, S. C. Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials, 2011, 32, 1890-1905.
77. Cukalevski, R.; Lundqvist, M.; Oslakovic, C.; Dahlback, B.; Linse, S.; Cedervall, T. Structural changes in apolipoproteins bound to nanoparticles. Langmuir, 2011, 27, 14360-14369.
78. Walkey, C.D.: Chan, W.C.; Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev., 2012, 41(7), 2780-2799.
79. Kodiyan, A.; Silva, E. A.; Kim, J.; Aizenberg, M.; Mooney, D. J. Surface modification with alginate-derived polymers for stable, protein-repellent, long-circulating gold nanoparticles. ACS Nano., 2012, 6, 4796-4805.
80. Hu, M.; Qian, L.; Brinas, R. P.; Lymar, E. S.; Hainfeld, J. F. Assembly of nanoparticle-protein binding complexes: from monomers to ordered arrays. Angew. Chem. Int. Ed. Engl., 2007, 46, 5111-5114. (Pubitemid 47051267)
81. Colvin, V. L.; Kulinowski, K. M. Nanoparticles as catalysts for protein fibrillation. Proc. Natl. Acad. Sci. U S A., 2007, 104, 8679-8680. (Pubitemid 47175369)
82. Hirano, A.; Yoshikawa, H.; Matsushita, S.; Yamada, Y.; Shiraki, K. Adsorption and disruption of lipid bilayers by nanoscale protein aggregates. Langmuir, 2012, 28, 3887-3895.
83. Chiti, F.; Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem., 2006, 75, 333-366. (Pubitemid 44118036)
84. Prapainop, K.; Witter, D. P.; Wentworth, P., Jr. A chemical approach for cell-specific targeting of nanomaterials: small-molecule-initiated misfolding of nanoparticle corona proteins. J. Am. Chem. Soc., 2012, 134, 4100-4103.
85. Thasneem, Y. M.; Sajeesh, S.; Sharma, C. P. Effect of thiol functionalization on the hemo-compatibility of PLGA nanoparticles. J. Biomed. Mater. Res A, 2011, 99, 607-617.
86. Kaur, K.; Forrest, J. A. Influence of particle size on the binding activity of proteins adsorbed onto gold nanoparticles. Langmuir, 2012, 28, 2736-2744.
87. Wiogo, H. T.; Lim, M.; Bulmus, V.; Gutiérrez, L.; Woodward, R. C.; Amal, R. Insight into Serum Protein Interactions with Function-alized Magnetic Nanoparticles in Biological Media. Langmuir, 2012, 28, 4346-4356.
88. Mangalathillam, S.; Rejinold, N. S.; Nair, A.; Lakshmanan, V. K.; Nair, S. V.; Jayakumar, R. Curcumin loaded chitin nanogels for skin cancer treatment via the transdermal route. Nanoscale, 2012, 4, 239-250.
89. Shah, N. B.; Vercellotti, G. M.; White, J. G.; Fegan, A.; Wagner, C. R.; Bischof, J. C. Blood-Nanoparticle Interactions and in Vivo Biodistribution: Impact of Surface PEG and Ligand Properties. Mol. Pharm., 2012, 9, 2146-2155.
90. Sohaebuddin, S. K.; Thevenot, P. T.; Baker, D.; Eaton, J. W.; Tang, L. Nanomaterial cytotoxicity is composition, size, and cell type dependent. Part Fibre Toxicol., 2010, 7, 22.
91. Dobrovolskaia, M. A.; Aggarwal, P.; Hall, J. B.; McNeil, S. E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm., 2008, 5, 487-495.